Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 3
2008 1
2009 3
2011 1
2012 1
2013 6
2014 1
2015 1
2016 1
2018 4
2019 3
2020 2
2021 1
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers.
Tang F, Kunder R, Chu T, Hains A, Nguyen A, McBride JM, Zhong Y, Santagostino S, Wilson M, Trenchak A, Chen L, Ly J, Moein A, Lewin-Koh N, Raghavan V, Osaghae U, Wynne C, Owen R, Place D. Tang F, et al. Among authors: wynne c. Clin Transl Sci. 2023 Sep;16(9):1653-1666. doi: 10.1111/cts.13576. Epub 2023 Jul 23. Clin Transl Sci. 2023. PMID: 37350225 Free PMC article. Clinical Trial.
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteers.
Zhu R, Chen H, Galanter J, She G, Cai F, Durk MR, Zou Y, Chen L, Kenny JR, Vadhavkar S, Warren S, Taylor G, Hwang O, Eliahu A, Wynne C, Owen R. Zhu R, et al. Among authors: wynne c. Clin Transl Sci. 2022 May;15(5):1225-1237. doi: 10.1111/cts.13240. Epub 2022 Feb 26. Clin Transl Sci. 2022. PMID: 35157370 Free PMC article. Clinical Trial.
Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.
Schwabe C, Illes A, Ullmann M, Ghori V, Vincent E, Petit-Frere C, Monnet J, Racault AS, Wynne C. Schwabe C, et al. Among authors: wynne c. Expert Rev Clin Immunol. 2022 May;18(5):533-543. doi: 10.1080/1744666X.2022.2060204. Epub 2022 Apr 10. Expert Rev Clin Immunol. 2022. PMID: 35354411 Clinical Trial.
A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.
Demarchi M, Coliat P, Barthelemy P, Schott R, BenAbdelghani M, Kim M, Hii JCS, Feyaerts P, Ang FRX, Derde MP, Deforce F, Petit T, Schwabe C, Wynne C, Park LS, Pivot X. Demarchi M, et al. Among authors: wynne c. PLoS One. 2021 Sep 23;16(9):e0248222. doi: 10.1371/journal.pone.0248222. eCollection 2021. PLoS One. 2021. PMID: 34555031 Free PMC article. Clinical Trial.
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
Kirschbrown WP, Wynne C, Kågedal M, Wada R, Li H, Wang B, Nijem I, Badovinac Crnjevic T, Gasser H, Heeson S, Eng-Wong J, Garg A. Kirschbrown WP, et al. Among authors: wynne c. J Clin Pharmacol. 2019 May;59(5):702-716. doi: 10.1002/jcph.1362. Epub 2018 Dec 19. J Clin Pharmacol. 2019. PMID: 30570763 Free PMC article. Clinical Trial.
30 results